RSS Feed
- 6. Boston Scientific received U.S. Food and Drug Administration (FDA) 510(k) clearance August 25, 2026Boston Scientific received U.S. Food and Drug Administration (FDA) 510(k) clearance for the expanded indication of Rezūm™ Water Vapor Therapy, increasing the maximum prostate volume that can be treated with the device from 80 cm3 to 150 cm3 for patients with benign prostatic hyperplasia (BPH). Existing real-world and clinical trial data for Rezūm Therapy demonstrates […]
- 4. PAPZIMEOS was granted full approval August 25, 2026PAPZIMEOS was granted full approval by the US Food and Drug Administration (FDA) in August 2025, becoming the first and only approved therapy for the treatment of adults with RRP. Effective April 1, 2026, a new, permanent HCPCS Level II J-code (J3404 - injection, zopapogene imadenovec-drba suspension, per therapeutic dose) will be available for the […]
- 5. Dyne Therapeutics August 25, 2026Dyne Therapeutics shared positive topline results from its Phase 1/2 trial of the investigational drug, zeleciment rostudirsen (also known as DYNE-251), in individuals with Duchenne muscular dystrophy amenable to exon 51 skipping. The study met its primary endpoint, demonstrating a statistically significant increase in dystrophin from baseline at 6 months. Furthermore, the treatment maintained a […]
- 13. LivaNova August 25, 2026LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, has announced that the journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study. The researchers evaluated the safety and efficacy of LivaNova's VNS Therapy™ System and its effectiveness on quality of life and daily function in […]
- Chief Healthcare Executive Roundtable: The promise and problems with value-based care August 25, 2026For years, healthcare leaders have discussed the need to shift away from the fee-for-service model of healthcare and move towards value-based care. During the Chief Healthcare Executive Roundtable, our panel of leaders said there is genuine potential with moving to a system that focuses on keeping people healthier. But they also said reimbursement models make […]
- 9. Gilead Sciences, Inc. August 25, 2026Gilead Sciences, Inc., a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, announced that the US Food and Drug Administration (FDA) has approved YEZTUGO® (lenacapavir) injection, 463.5 mg/1.5 mL. Click here for full Prescribing Information, including BOXED WARNING. Click here to learn more at YeztugoHCP.com.
- 11. NAMCP VBCC August 25, 2026NAMCP understands the changing landscape with regard to the delivery of healthcare moving from the traditional fee for service model to more of a focus on value based care and all of the complexities therein. The mission of the VBCC is to help payers and medical directors in their efforts to more effectively and efficiently […]
- Is the behavioral health access problem actually a quality problem? August 25, 2026Salt Lake City-based Intermountain Health is approaching behavioral health access challenges by first addressing one quality concern in particular: Whether patients are actually getting better.
- Pentagon 'SHINE' program researches traumatic brain injury treatments August 25, 2026DARPA has launched research aimed at improving treatment for traumatic brain injuries. Its Selective Harnessing of Intrinsic Neuroplasticity Engineering (SHINE) program is developing noninvasive tools to help the brain adapt after injury. The effort targets a condition affecting hundreds of thousands of veterans.
- As Candida auris spreads, UT Health San Antonio scientist highlights growing threat of antifungal resistance August 25, 2026As cases of the potentially deadly drug-resistant fungal infection Candida auris have spread to 27 states, including Texas with the second-highest number, a scientist at UT Health San Antonio, the academic health center of The University of Texas at San Antonio, warns that the problem of strains resistant to front-line antifungal medications is becoming increasingly […]
